Roivant Sciences surged 24% following positive Phase 2 trial results for subsidiary Pulmovant’s mosliciguat, which demonstrated clinically meaningful and statistically significant reduction in pulmonary vascular resistance for patients with pulmonary hypertension and interstitial lung disease.
Lockheed Martin gained 0.7% after UBS upgraded the defense contractor to buy from neutral, citing underappreciated earnings growth potential.
Novartis fell 12% after Phase 3 results showed its del-desiran drug failed to deliver significant improvement in patients with myotonic dystrophy type 1.
Peloton Interactive declined more than 4% following a Morgan Stanley downgrade to underweight from equal weight, with analysts citing structural headwinds in the fitness sector.
Boston Scientific slipped more than 2% after disclosing that a recent cyberattack likely impacted sales and profit targets for 2026.
Also Read
- Dynastic Politics’ Final Test: An Anti‑Establishment Primary Showdown
- Jaguar Land Rover to Trim 4,000 Positions as Part of Strategic Cost‑Reduction Plan
- United Kingdom Poised to Enact Economic Sanctions Against Occupied West Bank Settlements
- EU Leaders Denounce Serbia’s Funeral Tribute to Mladic, Membership Prospects at Risk
